APA (7th ed.) Citation

N, L., L, F., PI, G., V, S., PT, D., SR, O., . . . JM, B. (2018). Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology, 7(6), e1438106. https://doi.org/10.1080/2162402X.2018.1438106

Chicago Style (17th ed.) Citation

N, Luo, et al. "Melanoma Response to Anti-PD-L1 Immunotherapy Requires JAK1 Signaling, but Not JAK2." Oncoimmunology 7, no. 6 (2018): e1438106. https://doi.org/10.1080/2162402X.2018.1438106.

MLA (9th ed.) Citation

N, Luo, et al. "Melanoma Response to Anti-PD-L1 Immunotherapy Requires JAK1 Signaling, but Not JAK2." Oncoimmunology, vol. 7, no. 6, 2018, p. e1438106, https://doi.org/10.1080/2162402X.2018.1438106.